Ymmunobio
PrivateLast Round
Grant
Jan 23, 2025
Total Funding Raised
$1.93M
Company Overview
Ymmunobio is a drug discovery company developing first-in-class antibody-based therapies for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ymmunobio Comparables
Compare Ymmunobio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gilead Sciences | 81% | |
| Taiho Pharmaceutical Co., Ltd. | 77% | |
| Sotio | 77% | |
Ymmunobio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 23, 2025 | ||||
| Seed | Nov 13, 2023 |
Key People
Founding team and executive leadership
Ymmunobio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OKG Capital | Seed |
| Innosuisse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 23, 2025
$525K grant received from Innosuisse.
- Nov 13, 2023
$1.4M round led by OKG Capital
Ymmunobio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ymmunobio's valuation, stock price, and market status.